Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

BMI - Olivier Le Moal
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link

November 21st 2024

A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.

Doctor examining MRI images of multiple sclerosis MS | Image Credit: © New Africa - stock.adobe.com
Lesion Repair, Damage Processes Correlate With MS Disease Characteristics

November 11th 2024

Neurologic disease concept | image credit: ralwel - stock.adobe.com
Fexagratinib in MS Shows Promise for Human Use

November 9th 2024

MS word cloud | Image Credit: © arloo-stock.adobe.com
Exploring Metabolic Links to Cognitive Impairment in MS

November 8th 2024

Fingolimod | Image Credit: © María Pilar Martínez - stock.adobe.com
Fingolimod-Induced Heart Rate Slowing Tied to Parasympathetic Dominance in MS

October 26th 2024

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
November 23rd 2024

Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care

1.5 Credits / Neurology
November 23rd 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
November 23rd 2024

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
November 23rd 2024

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
November 23rd 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Dr Melinda Magyari Discusses Data on Treating Pediatric MS
November 18th 2019

Dr Melinda Magyari Discusses Data on Treating Pediatric MS

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).
Patients With MS Report That Depression, Fatigue Have Strongest Effect on Quality of Life
November 15th 2019

Patients With MS Report That Depression, Fatigue Have Strongest Effect on Quality of Life

Christina Mattina
Multiple sclerosis (MS) is known to be associated with lower health-related quality of life, and a new study adds evidence that depression and fatigue are the major drivers of this relationship.
Dr Alberto Ascherio Addresses Environmental Risk Factors for MS
November 11th 2019

Dr Alberto Ascherio Addresses Environmental Risk Factors for MS

Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, explains that, in addition to known environmental factors that affect multiple sclerosis (MS) risk, novel factors, such as childhood obesity, are also emerging.
Researchers Identify Genes With Potential to Predict Progression and Severity of MS
November 7th 2019

Researchers Identify Genes With Potential to Predict Progression and Severity of MS

Laura Joszt, MA
Researchers have identified complement genes that appear to play a role in vision loss associated with multiple sclerosis (MS), and this finding could help researchers monitor and predict the progression and severity of MS, according to a study published in Brain.
Dr Melinda Magyari Explains the Treatment Landscape for Pediatric-Onset MS
November 4th 2019

Dr Melinda Magyari Explains the Treatment Landscape for Pediatric-Onset MS

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).
The Need for a Patient Decision Aid in Multiple Sclerosis
November 1st 2019

The Need for a Patient Decision Aid in Multiple Sclerosis

Laura Joszt, MA
As the number of disease-modifying therapies available for multiple sclerosis increases, patients and physicians can struggle to identify the right one for the right patient, highlighting the need for a patient decision aid.
FDA Approves Diroximel Fumarate to Treat Relapsing Forms of MS
October 30th 2019

FDA Approves Diroximel Fumarate to Treat Relapsing Forms of MS

Kelly Davio
The FDA today approved Biogen and Alkermes’ diroximel fumarate, an oral agent, to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and secondary progressive disease. The drug, approved under the 505(b)(2) regulatory pathway on the basis of its bioequivalence to dimethyl fumarate (Tecfidera), will be sold as Vumerity.
Dr Jan Hillert Discusses Treatment Approaches in MS
October 28th 2019

Dr Jan Hillert Discusses Treatment Approaches in MS

Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden, discusses whether the medical community has reached a consensus on using an escalation approach to treatment or starting with highly effective therapies in treating multiple sclerosis (MS).
Using Serum Neurofilament Light Chains as a Biomarker of MS Disease Activity
October 23rd 2019

Using Serum Neurofilament Light Chains as a Biomarker of MS Disease Activity

Laura Joszt, MA
Serum neurofilament light chain is associated with brain atrophy and disability worsening, which means it can be used as an objective surrogate of ongoing disease activity in multiple sclerosis (MS), according to research published in JAMA Neurology.
Risk of Serious Infection for Patients With MS Varies Depending on Treatment
October 17th 2019

Risk of Serious Infection for Patients With MS Varies Depending on Treatment

Laura Joszt, MA
Patients with multiple sclerosis (MS) have a higher risk in general of infections, but the risk varies depending on their treatment, according to a new study in JAMA Neurology.
Dr Jan Hillert Addresses Stem Cell Transplants in Treating MS
October 14th 2019

Dr Jan Hillert Addresses Stem Cell Transplants in Treating MS

Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden, discusses the body of knowledge on using stem cell transplants to treat patients with multiple sclerosis (MS).
Treatment Patterns and Risk of Comorbidity Among Newly Diagnosed Patients With MS
October 12th 2019

Treatment Patterns and Risk of Comorbidity Among Newly Diagnosed Patients With MS

Laura Joszt, MA
Two abstracts presented at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, looked at patterns among patients newly diagnosed with multiple sclerosis (MS).
Comparing Efficacy of Ozanimod on Annualized Relapse Rate With Other DMTs
October 2nd 2019

Comparing Efficacy of Ozanimod on Annualized Relapse Rate With Other DMTs

Laura Joszt, MA
Ozanimod, under development to treat relapsing-remitting multiple sclerosis (RRMS), has greater efficacy on the annualized relapse rate (ARR) than most other first-line disease-modifying therapies (DMTs), according to 2 abstracts presented at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Dr Daniel Kantor Outlines Ways to Measure Disease Progression in MS
October 1st 2019

Dr Daniel Kantor Outlines Ways to Measure Disease Progression in MS

When measuring disease severity and progression in patients with multiple sclerosis (MS), there are several approaches that provide different information and have varying strengths and weaknesses, according to Daniel Kantor, MD, president of Kantor Neurology.
Key Biomarker in MS Associated With Diabetes in Study
September 27th 2019

Key Biomarker in MS Associated With Diabetes in Study

Mary Caffrey
Data on the link between elevated serum neurofilament light chain and diabetes was presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, held in Stockholm, Sweden.
AJMC® in the Press, September 27, 2019
September 27th 2019

AJMC® in the Press, September 27, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Dr Daniel Kantor Discusses the Troubling Occurrence of MS Underdiagnosis
September 24th 2019

Dr Daniel Kantor Discusses the Troubling Occurrence of MS Underdiagnosis

While there are concerns about the overdiagnosis of multiple sclerosis (MS), underdiagnosis is also a serious problem that can lead to patients not receiving treatment for MS, explained Daniel Kantor, MD, president of Kantor Neurology.
Patient-Reported Outcomes Gain Attention at ECTRIMS 2019
September 17th 2019

Patient-Reported Outcomes Gain Attention at ECTRIMS 2019

Mary Caffrey
Sessions and posters from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis discussed various ways to measure patient-reported outcomes in multiple sclerosis.
Dr Daniel Kantor on the Real-World Value of MS Disease Registries
September 16th 2019

Dr Daniel Kantor on the Real-World Value of MS Disease Registries

Since the introduction of disease-modifying therapies for multiple sclerosis (MS), evidence from disease registries has shown how the therapies work in the real world and reduce the effect of MS on people’s lives, according to Daniel Kantor, MD, president of Kantor Neurology.
Site Logo
September 13th 2019

Using New Tools to Assess Relapses, Progression in MS

Mary Caffrey
A joint session of ECTRIMS and the European Academy of Neurology assesses important topics in measuring relapse and progression in multiple sclerosis (MS).
AJMC® in the Press, September 13, 2019
September 13th 2019

AJMC® in the Press, September 13, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Dr Thomas Frisell Addresses Cardiac Safety of Ozanimod Versus Fingolimod in MS
September 13th 2019

Dr Thomas Frisell Addresses Cardiac Safety of Ozanimod Versus Fingolimod in MS

Patients with multiple sclerosis (MS) have a generally increased risk of cardiovascular disease, and some evidence is emerging that disease-modifying treatments may alter this risk. Thomas Frisell, PhD, coordinator of the Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, discusses whether newer treatments for MS, such as ozanimod, may present an improved cardiac safety profile for patients with MS versus older treatments, such as fingolimod.
Dr Andrew Solomon Discusses the Correct Application of the McDonald Criteria in Diagnosing MS
September 13th 2019

Dr Andrew Solomon Discusses the Correct Application of the McDonald Criteria in Diagnosing MS

Multiple sclerosis (MS) can be a challenging disease to diagnose because of its broad range of symptoms and because of the fact that many other syndromes can mimic MS. Additionally, the McDonald Criteria, which are clinical, radiographic, and laboratory criteria used for diagnosing MS, are sometimes misapplied, according to Andrew Solomon, MD, associate professor of neurological sciences and division chief of multiple sclerosis at Larner College of Medicine, The University of Vermont, Burlington, Vermont.
Site Logo
September 12th 2019

More Results for Ozanimod: DAYBREAK Data, Cognition and Gray Matter, Biomarker for Relapsing MS

Mary Caffrey
Results for ozanimod, which is under review by FDA and European regulators for treatment of relapsing multiple sclerosis (MS), were presented in poster sessions September 12, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Dr Viktor von Wyl Addresses the Impact of MS Disease Duration and Age on Disability Burden
September 12th 2019

Dr Viktor von Wyl Addresses the Impact of MS Disease Duration and Age on Disability Burden

Age is an important factor in the disease burden of multiple sclerosis (MS), as rising age both impacts disease course and brings with it additional risk of comorbidities. However, disease duration may be an even more important factor than age in reaching disability milestones, according to Viktor von Wyl, PhD, project leader, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Site Logo
September 12th 2019

Inebilizumab Results for NMOSD Presented at ECTRIMS, With Public Offering on Way

Mary Caffrey
FDA recently accepted the Biologics Licensing Application for inebilizumab to treat a rare autoimmune condition, neuromyelitis optica spectrum disorder. The results for inebilizumab were presented at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Dr Jan Hillert Discusses Emerging Therapeutic Targets for MS
September 12th 2019

Dr Jan Hillert Discusses Emerging Therapeutic Targets for MS

While current therapies for multiple sclerosis (MS) that treat focal inflammation are beneficial for many patients, there are other crucial aspects of the disease, including brain volume loss, that are not clearly linked to this inflammation and that demand new therapeutic developments, said Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden.
Site Logo
September 12th 2019

Better Therapies, Management of Comorbidities Improving Long-term Outcomes in MS, Speakers Say

Mary Caffrey
Speakers at a session at ECTRIMS 2019 on long-term outcomes in multiple sclerosis said that better therapies and improved understanding of the effect of comorbidities have improved outcomes. The session was part of the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Site Logo
September 11th 2019

Bringing Real-World Data to Multiple Sclerosis Treatment Decisions

Mary Caffrey
Maria Trojano, MD, professor of neurology at the University of Bari, Italy, offered the opening lecture at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Site Logo
September 11th 2019

Measure From RADIANCE Data Suggests Ozanimod More Effective in Slowing MS Disease Activity

Mary Caffrey
A poster featuring a post-hoc exploratory analysis of measures of thalamic volume from RADIANCE was presented September 11, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
<1
...
67891011121314
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo